Jazz Pharmaceuticals' Lung Cancer Setback: Stock Impact
A late-stage setback for Jazz Pharmaceuticals' lung cancer drug Zepzelca rattled investors, but the larger story may ...
For short-term financial goals, saving may be a wiser choice than investing. Understand the reasons behind this practical approach.
28,327 articlesA late-stage setback for Jazz Pharmaceuticals' lung cancer drug Zepzelca rattled investors, but the larger story may ...
Two memory names draw heavy investor attention as AI and data-center growth power demand. This guide examines whether...
A Google-backed study finds only 40% of U.S. workers casually use AI at work, with just 5% AI fluent. The result: big...
Alphabet raising $84.75 billion marks a bold turn in how tech giants fund AI bets. This article breaks down what it c...
Patience and a long time horizon are the most powerful tools in any investor’s kit. This guide explains why waiting f...
As policymakers migrate from restraint to regulation, Washington signals a bipartisan push for federal AI licensing, ...
Gary Keller argues that a data-driven view can outweigh market gloom, foreseeing 4.3 million home sales in 2026 and a...
When a fund exits its Brookdale Senior Living stake, it raises questions about momentum and risk. This guide breaks d...
Get a clear read on Deft's Q1 2026 results, margins, and guidance. This analysis shows what the deft 2026 earnings tr...
Lionsgate delivered stronger-than-expected results, and its stock jumped. This article breaks down the key factors be...
Robinhood's Vlad Tenev signals a pivot for crypto toward tokenized real-world assets, stepping away from meme coins a...
A famous public clash from 2013 reshaped how we think about money, risk, and accountability. This finance-forward loo...